Free Trial

Viatris (VTRS) Competitors

$10.41
-0.12 (-1.14%)
(As of 05/24/2024 ET)

VTRS vs. UTHR, SRPT, RDY, BMRN, BGNE, CTLT, ELAN, LEGN, CERE, and TEVA

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Dr. Reddy's Laboratories (RDY), BioMarin Pharmaceutical (BMRN), BeiGene (BGNE), Catalent (CTLT), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical preparations" industry.

Viatris vs.

United Therapeutics (NASDAQ:UTHR) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, community ranking, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

United Therapeutics received 550 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 61.80% of users gave United Therapeutics an outperform vote while only 35.59% of users gave Viatris an outperform vote.

CompanyUnderperformOutperform
United TherapeuticsOutperform Votes
571
61.80%
Underperform Votes
353
38.20%
ViatrisOutperform Votes
21
35.59%
Underperform Votes
38
64.41%

United Therapeutics has a net margin of 42.05% compared to United Therapeutics' net margin of -0.37%. Viatris' return on equity of 18.72% beat United Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
United Therapeutics42.05% 18.72% 15.35%
Viatris -0.37%16.63%7.10%

United Therapeutics currently has a consensus price target of $309.44, indicating a potential upside of 13.40%. Viatris has a consensus price target of $11.00, indicating a potential upside of 5.67%. Given Viatris' stronger consensus rating and higher probable upside, equities research analysts clearly believe United Therapeutics is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
United Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Viatris
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.33

In the previous week, United Therapeutics had 16 more articles in the media than Viatris. MarketBeat recorded 21 mentions for United Therapeutics and 5 mentions for Viatris. Viatris' average media sentiment score of 1.03 beat United Therapeutics' score of 0.41 indicating that United Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
United Therapeutics
12 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Viatris
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

94.1% of United Therapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 12.5% of United Therapeutics shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.

United Therapeutics has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
United Therapeutics$2.33B5.20$984.80M$21.1512.90
Viatris$15.43B0.80$54.70M-$0.06-173.50

Summary

United Therapeutics beats Viatris on 16 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.39B$6.73B$5.19B$8.06B
Dividend Yield4.41%2.67%2.83%3.93%
P/E Ratio-173.5016.54140.2917.24
Price / Sales0.80258.562,486.1080.08
Price / Cash2.0836.4636.1431.61
Price / Book0.625.795.434.60
Net Income$54.70M$130.57M$106.05M$214.07M
7 Day Performance-5.19%-2.46%-1.42%-1.11%
1 Month Performance-9.87%1.51%2.67%3.17%
1 Year Performance15.28%-6.56%3.35%7.84%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
4.8744 of 5 stars
$275.19
+0.2%
$309.44
+12.4%
+27.5%$12.21B$2.33B13.011,168Analyst Forecast
Insider Selling
Positive News
SRPT
Sarepta Therapeutics
4.757 of 5 stars
$129.12
-1.3%
$163.94
+27.0%
-6.0%$12.20B$1.24B1,173.821,314Options Volume
RDY
Dr. Reddy's Laboratories
1.1008 of 5 stars
$68.92
+0.3%
$81.00
+17.5%
+27.1%$11.47B$279.16B17.1025,863
BMRN
BioMarin Pharmaceutical
4.922 of 5 stars
$77.34
+0.4%
$106.11
+37.2%
-16.6%$14.69B$2.42B72.283,401
BGNE
BeiGene
3.0161 of 5 stars
$167.39
-4.0%
$251.93
+50.5%
-35.4%$16.02B$2.46B-22.1110,600Positive News
CTLT
Catalent
3.4494 of 5 stars
$55.01
+0.0%
$53.14
-3.4%
+46.3%$9.96B$4.28B-9.0217,800Analyst Forecast
Positive News
ELAN
Elanco Animal Health
3.0739 of 5 stars
$16.71
-1.7%
$18.29
+9.4%
+99.9%$8.26B$4.42B-6.319,300Insider Buying
News Coverage
LEGN
Legend Biotech
2.2553 of 5 stars
$42.96
-5.4%
$82.74
+92.6%
-37.3%$7.83B$342.80M-33.051,800Analyst Forecast
Analyst Revision
News Coverage
CERE
Cerevel Therapeutics
0.4638 of 5 stars
$41.77
-0.7%
$42.67
+2.1%
+24.9%$7.61BN/A0.00334
TEVA
Teva Pharmaceutical Industries
0.789 of 5 stars
$16.59
-1.3%
$14.22
-14.3%
+119.3%$18.60B$15.85B-40.4637,851

Related Companies and Tools

This page (NASDAQ:VTRS) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners